Bristol-Myers Squibb — manufacturer's medicines
Bristol-Myers Squibb
Bristol Myers Squibb (BMS) is an American biopharmaceutical company. It traces its roots to two firms: E. R. Squibb & Sons, founded by Edward Squibb in Brooklyn in 1858, and Bristol-Myers, which dates back to 1887 in Clinton, New York. The two merged in 1989. The company is headquartered in Princeton, New Jersey, and its shares trade on the New York Stock Exchange (NYSE).
BMS focuses on oncology and haematology, immunology and cardiovascular disease. Its key medicines include the immuno-oncology drug Opdivo (nivolumab), the anticoagulant Eliquis (apixaban), Revlimid (lenalidomide) for multiple myeloma and Sprycel (dasatinib) for chronic myeloid leukaemia.
In November 2019 BMS acquired the American biotech company Celgene for about 74 billion dollars, considerably strengthening its position in haematology. Revlimid and Abraxane — paclitaxel formulated as albumin-bound nanoparticles — were among the products that came to BMS with Celgene.
Unifarm carries Bristol Myers Squibb oncology medicines: Abraxane (nab-paclitaxel) and Sprycel (dasatinib).